Citation
Kumari, Kajol, et al. "Treatment With Testosterone Therapy in Type 2 Diabetic Hypogonadal Adult Males: a Systematic Review and Meta-Analysis." Clinics and Practice, vol. 13, no. 2, 2023, pp. 454-469.
Kumari K, Kumar R, Memon A, et al. Treatment with Testosterone Therapy in Type 2 Diabetic Hypogonadal Adult Males: A Systematic Review and Meta-Analysis. Clin Pract. 2023;13(2):454-469.
Kumari, K., Kumar, R., Memon, A., Kumari, B., Tehrim, M., Kumari, P., Shehryar, M., Islam, H., Islam, R., Khatri, M., Kumar, S., & Kumar, A. (2023). Treatment with Testosterone Therapy in Type 2 Diabetic Hypogonadal Adult Males: A Systematic Review and Meta-Analysis. Clinics and Practice, 13(2), 454-469. https://doi.org/10.3390/clinpract13020041
Kumari K, et al. Treatment With Testosterone Therapy in Type 2 Diabetic Hypogonadal Adult Males: a Systematic Review and Meta-Analysis. Clin Pract. 2023 Mar 20;13(2):454-469. PubMed PMID: 36961066.
TY - JOUR
T1 - Treatment with Testosterone Therapy in Type 2 Diabetic Hypogonadal Adult Males: A Systematic Review and Meta-Analysis.
AU - Kumari,Kajol,
AU - Kumar,Rohan,
AU - Memon,Areeba,
AU - Kumari,Beena,
AU - Tehrim,Moniba,
AU - Kumari,Pooja,
AU - Shehryar,Muhammad,
AU - Islam,Hamza,
AU - Islam,Rabia,
AU - Khatri,Mahima,
AU - Kumar,Satesh,
AU - Kumar,Ajay,
Y1 - 2023/03/20/
PY - 2023/02/05/received
PY - 2023/03/14/revised
PY - 2023/03/16/accepted
PY - 2023/3/24/entrez
PY - 2023/3/25/pubmed
PY - 2023/3/25/medline
KW - T2DM
KW - TRT
KW - hypogonadism
KW - low testosterone levels
KW - meta-analysis
KW - systematic review
KW - testosterone replacement therapy
KW - type 2 diabetes mellitus
SP - 454
EP - 469
JF - Clinics and practice
JO - Clin Pract
VL - 13
IS - 2
N2 - Testosterone replacement therapy (TRT) has been used to treat hypogonadal males with type 2 diabetes mellitus (T2DM) for a long time, despite variable results. This meta-analysis examines TRT's role in hypogonadal males with T2DM. The databases PubMed, Embase, and Google Scholar were searched for relevant RCTs and observational studies. Estimated pooled mean differences (MDs) and relative risks with 95% confidence intervals were used to measure the effects of TRT (CIs). When compared to the placebo, TRT improves glycemic management by significantly reducing glycated hemoglobin (HBA1c) levels (WMD = -0.29 [-0.57, -0.02] p = 0.04; I2 = 89.8%). Additionally, it reduces the homeostatic model assessment levels of insulin resistance (WMD = -1.47 [-3.14, 0.19]; p = 0.08; I2 = 56.3%), fasting glucose (WMD = -0.30 [-0.75, 0.15]; p = 0.19; I2 = 84.4%), and fasting insulin (WMD = -2.95 [-8.64, 2.74]; however, these results are non-significant. On the other hand, HBA1c levels are significantly reduced with TRT; in addition, total testosterone levels significantly increase with testosterone replacement therapy (WMD = 4.51 [2.40, 6.61] p = 0.0001; I2 = 96.3%). Based on our results, we hypothesize that TRT can improve glycemic control and hormone levels, as well as lower total cholesterol, triglyceride, and LDL cholesterol levels while raising HDL cholesterol in hypogonadal type 2 diabetes patients. To this end, we recommend TRT for these patients in addition to standard diabetes care.
SN - 2039-7275
UR - https://www.unboundmedicine.com/medline/citation/36961066/Treatment_with_Testosterone_Therapy_in_Type_2_Diabetic_Hypogonadal_Adult_Males:_A_Systematic_Review_and_Meta_Analysis_
DB - PRIME
DP - Unbound Medicine
ER -